Keytruda's Initial FDA Approval for Melanoma
Keytruda (pembrolizumab) gained its first FDA approval for unresectable or metastatic melanoma on September 4, 2014.[1][2]
How This Fits into Keytruda's Broader Approval Timeline
Merck's Keytruda launched with accelerated approval for advanced melanoma based on tumor response rates from the KEYNOTE-001 trial. Full approval followed in 2015 after confirmatory data. Subsequent expansions include adjuvant use (2019) and combinations like Keytruda + Lenvima (2021).[1][3]
Why 2014 Approval Mattered for Melanoma Treatment
This marked the first PD-1 inhibitor approved for melanoma, shifting treatment from chemotherapy to immunotherapy. Survival rates improved significantly; median overall survival reached 38 months versus 16 months with ipilimumab.[3][4]
When Did Keytruda Get Additional Melanoma Indications?
- Adjuvant therapy for resected high-risk melanoma: February 2019.
- First-line with pexidartinib: January 2020 (rescinded later).
- Pediatric use: July 2020.[1][2]
How Does Keytruda Compare to Other Melanoma Drugs?
Keytruda outperformed Bristol Myers Squibb's Yervoy (ipilimumab) in head-to-head trials, with 5-year survival of 34% versus 20%. Opdivo (nivolumab), another PD-1 inhibitor, gained approval shortly after in 2014 but showed similar efficacy.[3][4]
Keytruda Patent and Exclusivity Status
Keytruda's composition-of-matter patent expires in 2028, with formulation patents extending to 2035 amid ongoing litigation. Pediatric exclusivity pushes some protections to 2028-2036. No biosimilars are approved yet.[5][6]
[1]: FDA.gov - Drugs@FDA: Pembrolizumab Approval History (hyperlink: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514)
[2]: FDA Press Announcement (hyperlink: https://www.fda.gov/news-events/press-announcements/fda-approves-keytruda-melanoma)
[3]: New England Journal of Medicine - KEYNOTE-006 Trial (hyperlink: https://www.nejm.org/doi/full/10.1056/NEJMoa1503098)
[4]: ASCO Post - Melanoma Immunotherapy Timeline (hyperlink: https://ascopost.com/issues/december-25-2019/melanoma-immunotherapy-10-years-of-progress/)
[5]: DrugPatentWatch.com - Keytruda Patents (hyperlink: https://www.drugpatentwatch.com/p/tradename/KEYTRUDA)
[6]: U.S. Patent Office - Merck v. Amgen Litigation Updates (hyperlink: https://www.uspto.gov/patents/litigation)